ReviewPharmaceutical nanotechnology2026
A Comprehensive Review on Plant Bioactive Compounds-based Novel Drug Delivery System for the Treatment of Rheumatoid Arthritis.
Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid Arthritis (RA) is a chronic autoimmune disorder characterized by inflammation in the joints, leading to pain, swelling, stiffness, and eventual joint damage. This condition occurs when the body's immune system mistakenly attacks the synovium, the lining of the membranes surrounding the joints. Treatment focuses on reducing inflammation, alleviating pain, and preventing joint damage through a combination of medications, physical therapy, and lifestyle modifications. Recently, biological therapies have been introduced, including Tumour Necrosis Factor (TNF) blockers (such as etanercept, infliximab, and adalimumab), IL-6 inhibitors (tocilizumab), and interleukin- 1 inhibitors (anakinra). These treatments can lead to various side effects. The use of herbalbased treatments, such as secondary metabolites, has gained popularity due to their better tolerability, safety, and effectiveness compared to conventional therapies. However, there are also some limitations, like poor bioavailability and permeability and lower stability; to overcome these issues, Novel Drug Delivery Systems (NDDS) have been introduced as better treatment options in recent years. Polymer science advancements and nanotechnology applications have opened new avenues for RA treatment, emphasizing the development of smart drug delivery systems. These systems aim to improve therapeutic outcomes while minimizing adverse effects. Additionally, newly synthesized biocompatible drug delivery systems, combined with anti-inflammatory drugs composed of secondary metabolites, offer potential solutions for RA.
Indexed as
Identifiers
39716799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.